Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
Xue Bai(Shanxi University), Zhong‐Yi Dong(Nanfang Hospital), Shuai Kang(Shenyang Institute of Automation), Qiang Fu(Saint Louis University), Dehua Wu(Yangzhou University), Hongbo Zhu(Pudong Medical Center), Si-Cong Ma(Nanfang Hospital), Jian Wang(Qilu Hospital of Shandong University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Yuhan Chen(Pediatric Oncology Group), He-San Luo(Peter the Great St. Petersburg Polytechnic University), Hong‐Hong Yan(Sun Yat-sen University), Chuanhui Cao(Nanfang Hospital), Xin-Ran Tang(Nanfang Hospital)
Cited by 63
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k